



Dimerix

(ASX:DXB)

Investor Presentation

November 2021

Forward looking statements

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Dimerix to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition, the outcome of legal proceedings and the effectiveness of patent protection.




Dimerix

About Dimerix

About Dimerix

Dimerix is a biopharmaceutical company developing innovative new therapies in areas with unmet medical needs, with a core focus on inflammatory disease treatments such as kidney and respiratory diseases

Advancing **three near-term Phase 3** clinical studies



Demonstrated **clinical efficacy***; drug well understood, with **strong safety profile***

Patent protected products with **commercial manufacturing** established

Strong outlook with **significant value**** upside



Corporate overview



ASX

Ticker Symbol

ASX:DXB



Share price

~A\$0.27



Total ordinary shares on issue

320,873,666



Market Capitalisation

~A\$87 million



Average volume

1,177,054



Cash Balance (30Sep21)

A\$19 million*



Top 20 Shareholders own


35%

**includes \$10.3 million Placement and SPP funds received after quarter end*

Top shareholders

Position	Holder Name	Holding	% IC
1	Mr Peter Meurs	44,179,309	13.8%
2	Merchant Group & Nominees	17,925,000	5.6%
3	Bavaria Bay Pty Ltd	7,316,992	2.3%
4	Yodambao Pty Ltd	6,362,603	2.0%
5	Solequest Pty Ltd & Nominees	3,187,302	1.0%
6	Pfleger Family A/C & Nominees	3,137,874	1.0%
7	Rubi Holdings Pty Ltd	2,500,000	0.8%
7	Mr Andrew & Mrs Melinda Coates	2,500,000	0.8%
8	Jampaso Pty Ltd & Nominees	2,377,355	0.7%
9	Mr Richard Stanley De Ravin	2,350,000	0.7%
10	Mr Taylor Nicholas Green	2,150,000	0.7%
TOTAL (TOP 10)		49,807,126	29.3%

Pathway towards commercialisation



- ✓ Phase 3 study in FSGS initiating, with other pipeline products also progressing



- ✓ Two independent Phase 3 clinical studies underway in patients with COVID-19 respiratory complications




- ✓ DMX-200 manufacturing process optimised to improve commercial scalability and global logistics




- ✓ Favourable clinical efficacy and strong safety profile across multiple Phase 2 renal clinical studies demonstrated

- ✓ Orphan Drug Designation/accelerated approval pathway granted by US FDA, EU EMA and UK MHRA for FSGS




Development pipeline

5 product candidates in the pipeline, with 4 clinical opportunities



DMX-200 – working on inflammatory signalling pathway



DMX-200

- Small molecule – new chemical entity
- Inhibits activity of a cellular receptor of inflammation: CCR2
- 240mg oral delivery daily - 120mg capsule administered twice daily
- Administered to patients already on angiotensin receptor blocker (ARB)
- Extensive regulatory engagement – orphan designation secured in US, EU and UK


Kidney Disease Development Overview



FSGS phase 3 study design

Recruitment of first patient anticipated Q4 2021

A randomised, double-blind, multi-centre, placebo-controlled study of renal outcomes of DMX-200 in patients with primary FSGS receiving an ARB



Why FSGS: unmet need and market potential

FSGS: rare kidney disease characterized by inflammation and scarring of the kidney's filtration units, affecting children and adults[^]

Renal failure in <5 years from diagnosis – dialysis or transplant[^]

~20,000 FSGS patients in US with end-stage kidney disease - only ~1,000 receive kidney transplants each year[^]

Unfortunately, FSGS comes back to attack the new kidney 30-50% of the time[^]

**>US\$1 billion
addressable
market**
(80k US patients at
average orphan drug
pricing)

80,500 estimated in
US
210,000 FSGS
sufferers globally[#]

>16,000 new cases
diagnosed/year[#]

No current
approved therapies

FSGS diagnosis by
biopsy:
patient access to
payer/insurer = high
potential treatment
uptake

Average orphan
drug pricing,
>US\$7,000/mth
(US\$84,000/yr)*

For personal use only

COVID-19 Respiratory Complications

Potential benefits of DMX-200


Antiviral medications:
typically effective at preventing
damage caused by a virus when
administered
within 3-5 days of infection
(when many are asymptomatic)

DMX-200:
does not rely on early inhibition of
viral replication –
DMX-200 aims to prevent
damaging immune response
regardless of vaccination or
antiviral treatment


DMX-200:
may be beneficial for patients with
a wide range of respiratory
diseases in addition to COVID
(antivirals usually very specific for
a virus and sometimes even the
particular strain of the virus)



COVID-19 and pneumonia market potential



Two Phase 3 studies in COVID-19 patients



REMAP-CAP: COVID-19 pneumonia in ICU

- >475 patients recruited to the study domain
- WHO endorsed study
- primary endpoint = 21 day mortality



Funded by European Union through H2020
“Rapid European COVID-19 Emergency
Research response” (RECOVER) project



CLARITY 2.0: COVID-19 respiratory complications

- Recruiting >600 patients in India and Australia
- Primary endpoint = 14 day WHO Clinical Health Score

Run through the NHMRC Clinical trials centre and the University of Sydney

Secondary endpoint: recovery and quality of life
post hospitalisation (long-COVID assessment)



Initial study data anticipated Q1 2022




Additional longer
term propositions

Additional asset value propositions

Longer term opportunities

Diabetic Kidney Disease



Addressable market
US\$1.1 billion*

Key driver is the rise in diabetes global incidence

DKD

Diversifying
risk and
potential
sources of
revenue

COPD

Chronic Obstructive Pulmonary Disease



Global COPD treatment market (2017)
US\$14 billion**

* 2017 IQVIA ARB prescription and pricing data;

** <https://www.marketwatch.com/press-release/chronic-obstructive-pulmonary-disease-copd-therapeutics-market-global-industry-analysis-trends-market-size-and-forecasts-up-to-2030-2021-11-10?tesla=y>

For personal use only

Corporate Outlook



Potential value driving events

2021

2022

- ✓ DMX-200 demonstrated **encouraging clinical efficacy** and **strong safety profile** across multiple Phase 2 renal clinical studies
- ✓ Consistent advice received from **FDA, EMA and UK MHRA** on FSGS Phase 3 study design
- ✓ Orphan Drug Designation/**accelerated approval pathway** granted by US FDA, EU EMA and UK MHRA for FSGS
- ✓ Two independent Phase 3 clinical studies underway in patients with **COVID-19 respiratory complications**
- ✓ DMX-200 **manufacturing process optimised** to improve commercial scalability and global logistics
- ✓ DMX-700 in COPD progressed further towards **clinical development**
- ✓ Expansion of **IP portfolio**
- ✓ Strong **financial position**

- ✓ FSGS **ethics approval** and clinical **site initiations**
- ☐ FSGS Phase 3 study **recruitment** and first patient **first dose**
- ☐ REMAP-CAP Phase 3 COVID-19 study recruitment and **top line data**
- ☐ CLARITY 2.0 Phase 3 COVID-19 study recruitment and **top line data**
- ☐ DMX-700 for Chronic Obstructive Pulmonary Disease progression towards **clinical study**
- ☐ Diabetic kidney disease **clinical study** design and next steps
- ☐ Further expansion of **IP portfolio**
- ☐ FSGS **Phase 3 study Part 1 analysis** and progression to Part 2